Skip to main content
Premium Trial:

Request an Annual Quote

Affy and Qiagen Pen Collaboration on GeneChips, siRNA

NEW YORK, Oct. 31 (GenomeWeb News) - Affymetrix and Venlo, Netherlands-based Qiagen announced today that they have agreed to collaborate by using Affy's GeneChip to optimize Qiagen's siRNA technology.

 

The companies said that access to Affy's arrays would allow Qiagen to determine the on- and off-target effects of siRNA's silencing effect on a genome-wide scale.

 

"The whole-genome view that Affymetrix arrays offer will give researchers a more complete understanding of the downstream effects of siRNAs in their experiments and clinical research," Trevor Nicholls, Affy's chief commercial officer, said in a statement.

 

Financial terms of the agreement were not disclosed.

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.